Literature DB >> 26238119

Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Anthony B Miller1, Ronald Feld, Robert Fontana, John K Gohagan, Ismail Jatoi, Walter Lawrence, Amy Miller, Philip C ProroK, Ashwani Rajput, Morris Sherman, Gilbert Welch, Patrick Wright, Susan Yurgalevitch, Peter Albertsen.   

Abstract

Death review was conducted for the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial to avoid the biases associated with causes of death entered on death certificates. An algorithm selected deaths for review. Records on diagnosis and terminal illness were perused in the coordinating center and by the chair of the death review committee (DRC). Identifying information and randomization arm was removed. Three reviewers independently determined the cause of death. Disagreement was resolved at a meeting of the DRC. This process was subsequently simplified. The cause of death was determined by one DRC member and compared to the death certificate. With agreement the case was finalized. When discordant, the records were sent to a second DRC member. If the reviewers agreed, the case was finalized. If not, a third member reviewed. If two of the three reviewers agreed, the case was sent back to the discordant reviewer. If the reviewer remained discordant the case was resolved by a conference call. Of the 4728 death reviews that were completed, the DRC confirmed the death certificate underlying cause for over 90%. Between 5% and 13% of the certified deaths were regarded as indirect causes of death, associated with the treatment of the ascertained cancer; differential for prostate cancer, 11% in the intervention arm and 6% in the control. Without review, between 1% and 6% of the deaths that occurred would not have been assigned to the relevant PLCO cancer. The DRC completed 76% of those requiring review before the process ceased.

Entities:  

Mesh:

Year:  2015        PMID: 26238119     DOI: 10.2174/1574887110666150730120752

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN: 1574-8871


  12 in total

1.  Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial.

Authors:  Eric A Miller; Paul F Pinsky; Robert E Schoen; Philip C Prorok; Timothy R Church
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-11-29

2.  Cholecystokinin attenuates radiation-induced lung cancer cell apoptosis by modulating p53 gene transcription.

Authors:  Yi Han; Chongyu Su; Daping Yu; Shijie Zhou; Xiaoyun Song; Shuku Liu; Ming Qin; Yunsong Li; Ning Xiao; Xiaoqing Cao; Kang Shi; Xu Cheng; Zhidong Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

3.  Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Authors:  Paul F Pinsky; Philip C Prorok; Kelly Yu; Barnett S Kramer; Amanda Black; John K Gohagan; E David Crawford; Robert L Grubb; Gerald L Andriole
Journal:  Cancer       Date:  2016-12-01       Impact factor: 6.860

4.  Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort.

Authors:  Chad A Reichard; Bryan D Naelitz; Zeneng Wang; Xun Jia; Jianbo Li; Meir J Stampfer; Eric A Klein; Stanley L Hazen; Nima Sharifi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-10-28       Impact factor: 4.090

5.  Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Authors:  Paul F Pinsky; Kelly Yu; Barnett S Kramer; Amanda Black; Saundra S Buys; Edward Partridge; John Gohagan; Christine D Berg; Philip C Prorok
Journal:  Gynecol Oncol       Date:  2016-09-09       Impact factor: 5.482

6.  Impact of cause of death adjudication on the results of the European prostate cancer screening trial.

Authors:  Stephen D Walter; Harry J de Koning; Jonas Hugosson; Kirsi Talala; Monique J Roobol; Sigrid Carlsson; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Álvaro Páez; Sue Moss; Anssi Auvinen
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

7.  Errors in determination of net survival: cause-specific and relative survival settings.

Authors:  Chloe J Bright; Adam R Brentnall; Kate Wooldrage; Jonathon Myles; Peter Sasieni; Stephen W Duffy
Journal:  Br J Cancer       Date:  2020-02-10       Impact factor: 7.640

8.  In silico studies of piperazine derivatives as potent anti-proliferative agents against PC-3 prostate cancer cell lines.

Authors:  Fabian A Ikwu; Gideon A Shallangwa; Paul A Mamza; Adamu Uzairu
Journal:  Heliyon       Date:  2020-01-23

9.  Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.

Authors:  Emma L Turner; Chris Metcalfe; Jenny L Donovan; Sian Noble; Jonathan A C Sterne; J Athene Lane; Eleanor I Walsh; Elizabeth M Hill; Liz Down; Yoav Ben-Shlomo; Steven E Oliver; Simon Evans; Peter Brindle; Naomi J Williams; Laura J Hughes; Charlotte F Davies; Siaw Yein Ng; David E Neal; Freddie C Hamdy; Peter Albertsen; Colette M Reid; Jon Oxley; John McFarlane; Mary C Robinson; Jan Adolfsson; Anthony Zietman; Michael Baum; Anthony Koupparis; Richard M Martin
Journal:  Br J Cancer       Date:  2016-06-02       Impact factor: 7.640

10.  Outcome measures in clinical trials of treatments for acute severe haemorrhage.

Authors:  Amy Brenner; Monica Arribas; Jack Cuzick; Vipul Jairath; Simon Stanworth; Katharine Ker; Haleema Shakur-Still; Ian Roberts
Journal:  Trials       Date:  2018-10-01       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.